JUNE Medical Launches eVeck Colposcopy Plume Evacuation Kit

JUNE Medical has announced the launch of the eVeck Colposcopy Plume Evacuation Kit for the safe and efficient removal of surgical plume. Surgical plume is an unavoidable result of interventional procedures where diathermy, electrosurgery, laser and ultrasonic devices cut into tissue. It can release an unpleasant odour but, more importantly, can contain toxic, infectious or carcinogenic material – such as hydrogen peroxide gas, HPV or SARS-CoV-2 – that could be hazardous to theatre staff or indeed the patient. As a result, exposure to surgical plume has been linked to eye, nose and throat irritation, nausea, headaches, coughs, nasal congestion, asthma, and asthma-like symptoms.

The single-use eVeck Colposcopy Plume Kit comes ready assembled, with an integrated HEPA pre-filter, a flexi connector that fits assorted speculum models, and tubing that links to a plume evacuation system and is reinforced to prevent crushing and kinking. Renowned electro surgery consultant Steve Veck has worked on the project, advising medical device specialist Mosaic Surgical. He said: “Surgical plume is an inevitable consequence of procedures that use electrosurgical techniques, and there is clear evidence showing the dangers it presents to personnel. Despite this, the most efficient removal methods are not mandatory in every territory, or for every case. The eVeck eliminates this issue by attaching directly to the speculum, positioning it close to the surgical site to clear all the damaging materials before staff and patients can be exposed to them.”

Angela Spang, CEO of JUNE Medical, commented: “We are delighted to be able to offer this simple but vital solution that can prevent surgical teams from being exposed to the hazards of surgical plume. We hope that more widespread use of the eVeck Kit will have a significant long-term effect on improving the health of healthcare professionals.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”